

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Tablet****CAUTIONARY AND ADVISORY LABELS 21**

- ▶ **Rasilez** (Noden Pharma DAC)

Aliskiren (as Aliskiren hemifumarate) 150 mg Rasilez 150mg tablets | 28 tablet [PoM](#) £28.51 DT = £28.51

Aliskiren (as Aliskiren hemifumarate) 300 mg Rasilez 300mg tablets | 28 tablet [PoM](#) £34.27 DT = £34.27

## VASODILATORS > VASODILATOR ANTIHYPERTENSIVES

### Hydralazine hydrochloride

04-Feb-2020

- **INDICATIONS AND DOSE**

**Moderate to severe hypertension (adjunct)**

- ▶ **BY MOUTH**

- ▶ **Adult:** Initially 25 mg twice daily, increased if necessary up to 50 mg twice daily

**Heart failure (with long acting nitrate) (initiated in hospital or under specialist supervision)**

- ▶ **BY MOUTH**

- ▶ **Adult:** Initially 25 mg 3–4 times a day, subsequent doses to be increased every 2 days if necessary; usual maintenance 50–75 mg 4 times a day

**Hypertensive emergencies (including during pregnancy) | Hypertension with renal complications**

- ▶ **BY INTRAVENOUS INFUSION**

- ▶ **Adult:** Initially 200–300 micrograms/minute; usual maintenance 50–150 micrograms/minute

- ▶ **BY SLOW INTRAVENOUS INJECTION**

- ▶ **Adult:** 5–10 mg, to be diluted with 10 mL sodium chloride 0.9%; dose may be repeated after 20–30 minutes

- **CONTRA-INDICATIONS** Acute porphyrias p. 1120 · cor pulmonale · dissecting aortic aneurysm · high output heart failure · idiopathic systemic lupus erythematosus · myocardial insufficiency due to mechanical obstruction · severe tachycardia

- **CAUTIONS** Cerebrovascular disease · coronary artery disease (may provoke angina, avoid after myocardial infarction until stabilised) · occasionally blood pressure reduction too rapid even with low parental doses

- **INTERACTIONS** → Appendix 1: hydralazine

- **SIDE-EFFECTS**

- ▶ **Common or very common** Angina pectoris · diarrhoea · dizziness · flushing · gastrointestinal disorders · headache · hypotension · joint disorders · lupus-like syndrome (after long-term therapy with over 100 mg daily (or less in women and in slow acetylator individuals)) · myalgia · nasal congestion · nausea · palpitations · tachycardia · vomiting
- ▶ **Rare or very rare** Acute kidney injury · agranulocytosis · anaemia · anxiety · appetite decreased · conjunctivitis · depression · dyspnoea · eosinophilia · eye disorders · fever · glomerulonephritis · haematuria · haemolytic anaemia · hallucination · heart failure · hepatic disorders · leucocytosis · leucopenia · lymphadenopathy · malaise · nerve disorders · neutropenia · oedema · pancytopenia · paradoxical pressor response · paraesthesia · pleuritic pain · proteinuria · skin reactions · splenomegaly · thrombocytopenia · urinary retention · vasculitis · weight decreased

**SIDE-EFFECTS, FURTHER INFORMATION** The incidence of side-effects is lower if the dose is kept below 100mg daily, but systemic lupus erythematosus should be suspected if there is unexplained weight loss, arthritis, or any other unexplained ill health.

- **PREGNANCY** Neonatal thrombocytopenia reported, but risk should be balanced against risk of uncontrolled maternal hypertension. Manufacturer advises avoid before third trimester.

- **BREAST FEEDING** Present in milk but not known to be harmful.

**Monitoring** Monitor infant in breast-feeding.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution (risk of accumulation).

**Dose adjustments** Manufacturer advises adjust dose or dosing interval according to clinical response.

- **RENAL IMPAIRMENT**

**Dose adjustments** Reduce dose if eGFR less than 30 mL/minute/1.73 m<sup>2</sup>.

- **MONITORING REQUIREMENTS** Manufacturer advises test for antinuclear factor and for proteinuria every 6 months and check acetylator status before increasing dose above 100 mg daily, but evidence of clinical value unsatisfactory.

- **DIRECTIONS FOR ADMINISTRATION** For *intravenous infusion* (*Apresoline*®) give continuously in Sodium chloride 0.9%. Suggested infusion volume 500 mL.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

**Tablet**

EXCIPIENTS: May contain Gluten, propylene glycol

- ▶ **Hydralazine hydrochloride (Non-proprietary)**

**Hydralazine hydrochloride 10 mg** Apo-Hydralazine 10mg tablets | 100 tablet [PoM](#) [S](#)

**Hydralazine hydrochloride 25 mg** Hydralazine 25mg tablets | 56 tablet [PoM](#) £7.37 DT = £5.64 | 84 tablet [PoM](#) £14.00

**Hydralazine hydrochloride 50 mg** Hydralazine 50mg tablets | 56 tablet [PoM](#) £15.46 DT = £8.11

- ▶ **Apresoline** (Advanz Pharma)

**Hydralazine hydrochloride 25 mg** Apresoline 25mg tablets | 84 tablet [PoM](#) £3.38

**Powder for solution for injection**

- ▶ **Hydralazine hydrochloride (Non-proprietary)**

**Hydralazine hydrochloride 20 mg** Hydralazine 20mg powder for concentrate for solution for injection ampoules | 5 ampoule [PoM](#) £74.17

### Minoxidil

01-May-2020

- **INDICATIONS AND DOSE**

**Severe hypertension, in addition to a diuretic and a beta-blocker**

- ▶ **BY MOUTH**

- ▶ **Adult:** Initially 5 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg, increased at intervals of at least 3 days; maximum 100 mg per day

- ▶ **Elderly:** Initially 2.5 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg, increased at intervals of at least 3 days; maximum 100 mg per day

- **CONTRA-INDICATIONS** Phaeochromocytoma

- **CAUTIONS** Acute porphyrias p. 1120 · after myocardial infarction (until stabilised) · angina

- **INTERACTIONS** → Appendix 1: minoxidil

- **SIDE-EFFECTS**

- ▶ **Common or very common** Fluid retention · hair changes · oedema · pericardial disorders · pericarditis · tachycardia

- ▶ **Rare or very rare** Leucopenia · skin reactions · Stevens-Johnson syndrome · thrombocytopenia

- ▶ **Frequency not known** Angina pectoris · breast tenderness · gastrointestinal disorder · pleural effusion · sodium retention · weight increased

- **PREGNANCY** Avoid—possible toxicity including reduced placental perfusion. Neonatal hirsutism reported.